公开(公告)号：US20250108055A1

公开(公告)日：2025-04-03

申请号：US18906104

申请日：2024-10-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Ruth Wei Aranda ,  James Gail Christensen ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12171765B2

公开(公告)日：2024-12-24

申请号：US17713455

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

公开(公告)号：US20240408099A1

公开(公告)日：2024-12-12

申请号：US18694867

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/517 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12128048B2

公开(公告)日：2024-10-29

申请号：US17713472

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/502 ,  A61K2300/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US20240270719A1

公开(公告)日：2024-08-15

申请号：US18437950

申请日：2024-02-09

Applicant: Mirati Therapeutics, Inc.

Inventor： Michal Achmatowicz ,  Svitlana Kulyk ,  Christopher Ronald Smith ,  Nan Wang ,  Harsh Shah ,  Tian Xie ,  Qi Gao

IPC: C07D403/04

CPC classification number: C07D403/04

Abstract: Disclosed herein are crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile free base, pharmaceutically acceptable compositions comprising these crystalline forms, and methods for using these crystalline forms.

公开(公告)号：US20230321062A1

公开(公告)日：2023-10-12

申请号：US18026799

申请日：2021-09-15

Applicant: Mirati Therapeutics, Inc.

Inventor： Hirak Der-Torossian

IPC: A61K31/444 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00

CPC classification number: A61K31/444 ,  A61K39/3955 ,  A61K47/6803 ,  A61P35/00 ,  A61K2039/507

Abstract: The present invention relates to combination therapies for treating cancer, in particular a multityrosine kinase-associated cancer. The present invention provides therapeutically effective combinations of: a) N-(3-Fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy) phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (aka sitravatinib); plus b) a PD-(L)1/PD-1 checkpoint inhibitor; and/or c) the Nectin-4 directed antibody-drug conjugate; as well as methods of using these combinations to treat cancer.

公开(公告)号：US20230137886A1

公开(公告)日：2023-05-04

申请号：US18071384

申请日：2022-11-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Aaron Craig Burns ,  Xiaolun Wang ,  Svitlana Kulyk ,  Anthony Ivetac

IPC: C07D487/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D403/04 ,  C07D487/08 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  C07D471/08 ,  C07D237/34

Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.

公开(公告)号：US20230077225A1

公开(公告)日：2023-03-09

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230054883A1

公开(公告)日：2023-02-23

申请号：US17942367

申请日：2022-09-12

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D471/04 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D401/14 ,  C07D487/04 ,  C12N9/10

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20220402936A1

公开(公告)日：2022-12-22

申请号：US17762713

申请日：2020-09-09

Applicant: Mirati Therapeutics, Inc.

Inventor： Franck Raeppel ,  Stephane L. Raeppel

IPC: C07D495/04 ,  A61P35/00

Abstract: The present invention relates to crystalline forms of N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.